- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 25th, 2005
Lumera Corp. announced it has acquired the exclusive rights to Helix Biopharma's Heterodimer Protein Technology (HPT). The technology moves Lumera closer to launching a unique product set aimed to capitalize on the multi-billion dollar proteomic array market.
The combination of the Helix HPT technology and Lumera's proprietary nanosurface modification chemistry will, for the first time, allow researchers to consistently take existing DNA arrays to produce protein arrays that accurately mimic the native living cell environment of the body.
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
A nano-roundabout for light December 10th, 2016
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016